文献速递冠心病瓣膜病与结构性心脏病

有创冠状动脉功能检测在无阻塞性冠心病心绞痛患者中的随机对照试验

Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial.
PubMed 文献 · Circulation · 2023-10-05

本研究前瞻性筛查英国3家医院因心绞痛行冠状动脉CT血管造影的无阻塞性冠状动脉患者,随机分为公开有创冠状动脉功能检测结果组与盲法对照组。主要终点为基于冠状动脉CT血管造影的初始诊断与有创内皮分型后最终诊断之间的重新分类率组间差异。结果显示,公开检测结果使冠状动脉血管运动障碍诊断率提高至76.5%,治疗满意度在12个月时改善,但长期心绞痛负担无差异。

要点

  • 有创冠状动脉功能检测可显著提高冠状动脉血管运动障碍的诊断率(OR 4.05)。
  • 公开检测结果未改善长期心绞痛负担(SAQ总结评分组间无差异)。
  • 公开检测结果与12个月时治疗满意度改善相关。

核心结论

  • 对于有心绞痛但无阻塞性冠状动脉的患者,基于有创功能评估的诊断对长期心绞痛负担无影响,但治疗满意度改善。

研究设计与样本

  • 前瞻性随机对照试验,在英国3家医院筛查因心绞痛行冠状动脉CT血管造影的门诊患者。
  • 250例(77.6%)患者接受有创内皮分型,其中231例随机分组并随访(平均年龄55.7岁,女性64.5%,中位随访19.9个月)。

主要发现

  • 有创内皮分型显示:7.6%有阻塞性冠状动脉疾病,55.0%有微血管性心绞痛,11.7%有血管痉挛性心绞痛,7.4%两者兼有,26.0%无异常。
  • 随机分组后,干预组被诊断为冠状动脉血管运动障碍的可能性是对照组的4倍(OR 4.05,95%CI 2.32-7.24,P<0.001),诊断频率增至76.5%。
  • 冠状动脉功能正常(无血管运动障碍)的频率在随机分组前两组无差异(51.3% vs 50.9%),随机分组后在干预组降低(23.5% vs 50.9%,P<0.001)。
  • 6个月和12个月时,西雅图心绞痛问卷总结评分在干预组与对照组之间无差异(全局P=0.36)。
  • 与对照组相比,干预组在12个月时整体治疗满意度更高(69.9±22.8 vs 61.7±26.9,P=0.013)。

关键数值与推荐

  • 冠状动脉血流储备异常定义为<2.0。
  • 微血管阻力指数异常定义为≥25。
  • 乙酰胆碱冠状动脉内输注浓度分别为0.182、1.82和18.2 μg/mL,以2 mL/min输注2分钟,用于评估微血管和冠状动脉痉挛。
  • 血流储备分数≤0.80的患者被排除。

临床怎么用

  • 对于无阻塞性冠状动脉的心绞痛患者,可考虑有创冠状动脉功能检测以明确血管运动障碍诊断。
  • 检测结果公开可能提高治疗满意度,但不应期望其显著减轻长期心绞痛负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries. METHODS: Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened. After coronary computed tomography angiography, patients with unobstructed coronary arteries, and who consented, underwent invasive endotyping. The diagnostic assessments included coronary angiography, fractional flow reserve (patient excluded if ≤0.80), and, for those without obstructive coronary artery disease, coronary flow reserve (abnormal <2.0), index of microvascular resistance (abnormal ≥25), and intracoronary infusion of acetylcholine (0.182, 1.82, and 18.2 μg/mL; 2 mL/min for 2 minutes) to assess for microvascular and coronary spasm. Participants were randomly assigned to disclosure of the results of the coronary function tests to the invasive cardiologist (intervention group) or nondisclosure (control group, blinded). In the control group, a diagnosis of vasomotor angina was based on medical history, noninvasive tests, and coronary angiography. The primary outcome was the between-group difference in the reclassification rate of the initial diagnosis on the basis of coronary computed tomography angiography versus the final diagnosis after invasive endotyping. The Seattle Angina Questionnaire summary score and Treatment Satisfaction Questionnaire for Medication were secondary outcomes. RESULTS: Of 322 eligible patients, 250 (77.6%) underwent invasive endotyping; 19 (7.6%) had obstructive coronary disease, 127 (55.0%) had microvascular angina, 27 (11.7%) had vasospastic angina, 17 (7.4%) had both, and 60 (26.0%) had no abnormality. A total of 231 patients (mean age, 55.7 years; 64.5% women) were randomly assigned and followed up (median duration, 19.9 [12.6-26.9] months). The clinician diagnosed vasomotor angina in 51 (44.3%) patients in the intervention group and in 55 (47.4%) patients in the control group. After randomization, patients in the intervention group were 4-fold (odds ratio, 4.05 [95% CI, 2.32-7.24]; P<0.001) more likely to be diagnosed with a coronary vasomotor disorder; the frequency of this diagnosis increased to 76.5%. The frequency of normal coronary function (ie, no vasomotor disorder) was not different between the groups before randomization (51.3% versus 50.9%) but was reduced in the intervention group after randomization (23.5% versus 50.9%, P<0.001). At 6 and 12 months, the Seattle Angina Questionnaire summary score in the intervention versus control groups was 59.2±24.2 (2.3±16.2 change from baseline) versus 60.4±23.9 (4.6±16.4 change) and 63.7±23.5 (4.7±14.7 change) versus 66.0±19.3 (7.9±17.1 change), respectively, and not different between groups (global P=0.36). Compared with the control group, global treatment satisfaction was higher in the intervention group at 12 months (69.9±22.8 versus 61.7±26.9, P=0.013). CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03477890.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Sidik NP, Stanley B, Sykes R, et al. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial. Circulation. 2023. PMID: 37795617. doi:10.1161/CIRCULATIONAHA.123.064751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。